MA29212B1 - Vaccins contre la malaria du type primo-immunisation/rappel ('prime/boost') - Google Patents

Vaccins contre la malaria du type primo-immunisation/rappel ('prime/boost')

Info

Publication number
MA29212B1
MA29212B1 MA29903A MA29903A MA29212B1 MA 29212 B1 MA29212 B1 MA 29212B1 MA 29903 A MA29903 A MA 29903A MA 29903 A MA29903 A MA 29903A MA 29212 B1 MA29212 B1 MA 29212B1
Authority
MA
Morocco
Prior art keywords
primo
immunization
boost
prime
malaria vaccines
Prior art date
Application number
MA29903A
Other languages
English (en)
Inventor
Maria Grazia Pau
Jaap Goudsmit
Joseph D Cohen
Patrice M Dubois
Ann V Stewart
Donald Heppner
Original Assignee
Crucell Holland Bv
Us Gov Sec Army
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crucell Holland Bv, Us Gov Sec Army, Glaxosmithkline Biolog Sa filed Critical Crucell Holland Bv
Publication of MA29212B1 publication Critical patent/MA29212B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'INVENTION CONCERNE DE NOUVELLES STRATÉGIES DE VACCINATION, DANS LESQUELLES DES STRATÉGIES DU TYPE PRIMO-IMMUNISATION/RAPPEL ('PRIME/BOOST') SPÉCIFIQUES SONT APPLIQUÉES À L'AIDE DE VECTEURS ADÉNOVIRAUX RECOMBINÉS FAIBLEMENT NEUTRALISÉS, QUI CONTIENNENT DES ACIDES NUCLÉIQUES CODANT POUR DES ANTIGÈNES DE PLASMODIUM FALCIPARUM; ET DES VACCINS À BASE DE PROTÉINES RECOMBINÉES PURIFIÉES TELLES QUE RTS,S, QUI COMPRENNENT DES ADJUVANTS APPROPRIÉS.
MA29903A 2004-10-14 2007-05-14 Vaccins contre la malaria du type primo-immunisation/rappel ('prime/boost') MA29212B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61905604P 2004-10-14 2004-10-14
EP04105035 2004-10-14

Publications (1)

Publication Number Publication Date
MA29212B1 true MA29212B1 (fr) 2008-02-01

Family

ID=34929701

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29903A MA29212B1 (fr) 2004-10-14 2007-05-14 Vaccins contre la malaria du type primo-immunisation/rappel ('prime/boost')

Country Status (25)

Country Link
US (3) US20080131461A1 (fr)
EP (1) EP1802336B1 (fr)
JP (1) JP5108521B2 (fr)
KR (1) KR20070104881A (fr)
CN (1) CN101068568B (fr)
AT (1) ATE523205T1 (fr)
AU (1) AU2005293572B2 (fr)
BR (1) BRPI0518146A (fr)
CA (1) CA2582455A1 (fr)
CY (1) CY1112749T1 (fr)
DK (1) DK1802336T3 (fr)
EA (1) EA016648B1 (fr)
ES (1) ES2371175T3 (fr)
HK (1) HK1100121A1 (fr)
HR (1) HRP20110786T1 (fr)
IL (2) IL182357A0 (fr)
MA (1) MA29212B1 (fr)
MX (1) MX2007004031A (fr)
NO (1) NO20072470L (fr)
NZ (1) NZ583291A (fr)
PL (1) PL1802336T3 (fr)
PT (1) PT1802336E (fr)
RS (1) RS52187B (fr)
SI (1) SI1802336T1 (fr)
WO (1) WO2006040334A1 (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0833934T4 (da) 1995-06-15 2012-11-19 Crucell Holland Bv Pakningssystemer til human rekombinant adenovirus til anvendelse ved genterapi
US6929946B1 (en) * 1998-11-20 2005-08-16 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
US7504248B2 (en) * 2001-12-07 2009-03-17 Crucell Holland B.V. Production of viruses viral isolates and vaccines
US20050164386A1 (en) * 1999-04-15 2005-07-28 Uytdehaag Alphonsus G. Overexpression of enzymes involved in post-translational protein modifications in human cells
US20050002958A1 (en) * 1999-06-29 2005-01-06 Smithkline Beecham Biologicals Sa Vaccines
US7521220B2 (en) * 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
US7192759B1 (en) * 1999-11-26 2007-03-20 Crucell Holland B.V. Production of vaccines
WO2004055187A1 (fr) * 2002-12-17 2004-07-01 Crucell Holland B.V. Vaccins contre la malaria a base virale recombinante
KR101206206B1 (ko) * 2003-07-22 2012-11-29 크루셀 홀란드 비.브이. 사스-코로나바이러스에 대한 결합분자 및 그것의 용도
JP5108521B2 (ja) * 2004-10-14 2012-12-26 クルセル ホランド ベー ヴェー マラリア初回免疫／追加免疫ワクチン
GB0513421D0 (en) 2005-06-30 2005-08-03 Glaxosmithkline Biolog Sa Vaccines
EP1998804B1 (fr) * 2006-03-27 2014-04-16 Crucell Holland B.V. Compositions comprenant un adénovirus recombiné et un adjuvant
US9717788B2 (en) 2007-03-02 2017-08-01 Glaxosmithkline Biologicals Sa Method of inducing an immune response against HIV employing HIV immunogens, adenoviral vectors encoding said immunogens, and adjuvant
NZ583150A (en) 2007-08-13 2012-05-25 Glaxosmithkline Biolog Sa Use of an antigen derived from the circumsporozoite protein (CS) protein of Plasmodium falciparum in the manufacture of a medicament for vaccinating infants against malaria
CN101883858B (zh) 2007-11-28 2015-07-22 宾夕法尼亚大学托管会 猿猴亚家族E腺病毒SAdV-39、-25.2、-26、-30、-37和-38及其应用
LT2220242T (lt) 2007-11-28 2017-04-10 The Trustees Of The University Of Pennsylvania Simian pošeimio b adenovirusai sadv-28,27,-29,-32,-33 ir -35 ir jų panaudojimas
TW200938633A (en) * 2007-12-06 2009-09-16 Glaxosmithkline Biolog Sa Vaccine
EP2325298B1 (fr) 2008-03-04 2016-10-05 The Trustees Of The University Of Pennsylvania ADENOVIRUS DE SINGE SAdV-36, -42.1, -42.2, AND -44 ET LEUR UTILISATION
WO2010040000A2 (fr) * 2008-10-01 2010-04-08 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Vaccin multicomposant contre la malaria induisant des réponses immunitaires durables contre le plasmodium
DK2350268T3 (en) * 2008-11-03 2015-03-23 Crucell Holland Bv PROCEDURE FOR PRODUCING ADENOVIRUS VECTORS
SG177655A1 (en) * 2009-07-16 2012-02-28 Crucell Holland Bv Production of polio virus at high titers for vaccine production
MX354752B (es) 2010-09-27 2018-03-20 Janssen Vaccines & Prevention Bv Regimen de vacunacion de sensibilizacion y refuerzo heterologo contra malaria.
PL2655604T3 (pl) * 2010-12-14 2019-02-28 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Szczepionki adenowirusowe serotyp 26 i serotyp 35 przeciwko filowirusom
JP6054942B2 (ja) * 2011-04-08 2016-12-27 イミューン デザイン コーポレイション 免疫原性組成物、ならびに体液性および細胞性免疫応答を誘発するための該組成物の使用方法
AU2013221187B9 (en) 2012-02-16 2018-01-04 Vlp Therapeutics, Inc. Virus like particle composition
CN105473723A (zh) 2012-05-18 2016-04-06 宾夕法尼亚大学托管会 亚家族e猿腺病毒a1302、a1320、a1331和a1337及其用途
SG10201709917VA (en) * 2013-06-03 2017-12-28 Vlp Therapeutics Llc Malaria vaccine
TWI676636B (zh) 2013-07-12 2019-11-11 Ｖｌｐ醫療股份有限公司 包含ｐｄ－１抗原或ｐｄ－１配體抗原的類病毒粒子
US9321834B2 (en) 2013-12-05 2016-04-26 Leidos, Inc. Anti-malarial compositions
GB201405921D0 (en) 2014-04-02 2014-05-14 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
WO2015197823A2 (fr) 2014-06-26 2015-12-30 Crucell Holland B.V. Anticorps et fragments de liaison à l'antigène qui se lient spécifiquement à la protéine tau associée aux microtubules
ZA201608812B (en) 2014-06-26 2019-08-28 Janssen Vaccines & Prevention Bv Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
EP3177720B1 (fr) 2014-08-08 2021-09-22 VLP Therapeutics, Inc. Particule analogue à un virus comprenant une protéine d'enveloppe e3 modifiée
US10385101B2 (en) 2014-08-08 2019-08-20 Vlp Therapeutics, Llc Virus like particle comprising modified envelope protein E3
SG11201701669PA (en) 2014-09-11 2017-04-27 Vlp Therapeutics Llc Flavivirus virus like particle
JPWO2016059911A1 (ja) * 2014-10-17 2017-07-27 国立大学法人金沢大学 マラリアワクチン
EP3600399A4 (fr) * 2017-03-30 2021-03-24 The United States of America, as represented by the Secretary of the Navy Procédés et compositions pour vacciner contre le paludisme
EP3755369A4 (fr) * 2018-02-22 2022-01-19 Turnstone Limited Partnership Virus oncolytiques en tant qu'adjuvants
US20220040281A1 (en) * 2018-12-21 2022-02-10 Curevac Ag Rna for malaria vaccines
JP2023520370A (ja) 2020-03-27 2023-05-17 スヴェンスカ ヴァクチンファブリケン プロダクション アーベー コロナウイルスの治療および予防のための組成物および方法
TW202330575A (zh) 2021-09-29 2023-08-01 瑞典商斯文斯卡疫苗生產股份有限公司 用於治療及預防冠狀病毒之組成物及方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6306625B1 (en) * 1988-12-30 2001-10-23 Smithkline Beecham Biologicals, Sa Method for obtaining expression of mixed polypeptide particles in yeast
AU2927892A (en) * 1991-11-16 1993-06-15 Smithkline Beecham Biologicals (Sa) Hybrid protein between cs from plasmodium and hbsag
FR2763959A1 (fr) * 1997-06-02 1998-12-04 Transgene Sa Nouveaux vecteurs adenoviraux recombinants comprenant une sequence d'epissage
US7604960B2 (en) * 1999-04-15 2009-10-20 Crucell Holland B.V. Transient protein expression methods
US20050164386A1 (en) * 1999-04-15 2005-07-28 Uytdehaag Alphonsus G. Overexpression of enzymes involved in post-translational protein modifications in human cells
US7504248B2 (en) * 2001-12-07 2009-03-17 Crucell Holland B.V. Production of viruses viral isolates and vaccines
US7192759B1 (en) * 1999-11-26 2007-03-20 Crucell Holland B.V. Production of vaccines
US7527961B2 (en) * 1999-11-26 2009-05-05 Crucell Holland B.V. Production of vaccines
US7521220B2 (en) * 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
US20080153083A1 (en) * 2003-10-23 2008-06-26 Crucell Holland B.V. Settings for recombinant adenoviral-based vaccines
AU2003288273A1 (en) * 2002-10-23 2004-05-13 Crucell Holland B.V. New settings for recombinant adenoviral-based vaccines
US7491395B2 (en) * 2002-11-20 2009-02-17 Bestewil Holding B.V. Compositions comprising antigen-complexes, method of making same as well as methods of using the antigen-complexes for vaccination
WO2004055187A1 (fr) * 2002-12-17 2004-07-01 Crucell Holland B.V. Vaccins contre la malaria a base virale recombinante
KR101206206B1 (ko) * 2003-07-22 2012-11-29 크루셀 홀란드 비.브이. 사스-코로나바이러스에 대한 결합분자 및 그것의 용도
JP5108521B2 (ja) * 2004-10-14 2012-12-26 クルセル ホランド ベー ヴェー マラリア初回免疫／追加免疫ワクチン
SG159542A1 (en) * 2004-11-11 2010-03-30 Crucell Holland Bv Compositions against sars-coronavirus and uses thereof

Also Published As

Publication number Publication date
US20080131461A1 (en) 2008-06-05
MX2007004031A (es) 2007-11-08
RS52187B (en) 2012-10-31
AU2005293572A1 (en) 2006-04-20
JP2008516926A (ja) 2008-05-22
IL214460A0 (en) 2011-09-27
PL1802336T3 (pl) 2012-03-30
US20090285879A1 (en) 2009-11-19
EP1802336A1 (fr) 2007-07-04
EP1802336B1 (fr) 2011-09-07
DK1802336T3 (da) 2011-11-14
HRP20110786T1 (hr) 2011-12-31
IL182357A0 (en) 2007-07-24
BRPI0518146A (pt) 2008-10-28
NO20072470L (no) 2007-07-16
HK1100121A1 (en) 2007-09-07
CY1112749T1 (el) 2016-02-10
ATE523205T1 (de) 2011-09-15
US20120014994A1 (en) 2012-01-19
CN101068568B (zh) 2012-09-26
JP5108521B2 (ja) 2012-12-26
SI1802336T1 (sl) 2012-01-31
WO2006040334A1 (fr) 2006-04-20
EA016648B1 (ru) 2012-06-29
EA200700849A1 (ru) 2007-10-26
PT1802336E (pt) 2011-11-15
AU2005293572B2 (en) 2011-08-04
KR20070104881A (ko) 2007-10-29
ES2371175T3 (es) 2011-12-28
CN101068568A (zh) 2007-11-07
NZ583291A (en) 2011-06-30
CA2582455A1 (fr) 2006-04-20

Similar Documents

Publication Publication Date Title
MA29212B1 (fr) Vaccins contre la malaria du type primo-immunisation/rappel ('prime/boost')
PT1487485E (pt) Adjuvantes de imidazoquinolina para vacinas de adn
WO2006066214A3 (fr) Utilisation de la flagelline dans l'immunotherapie de yersinia pestis
HUP0303753A2 (hu) Fúziós fehérjék immunogenitásának csökkentése
WO2003059381A3 (fr) Préparations immunogènes et vaccins à base d'arn
IL205958A0 (en) Immunogenic composition and method of developing a vaccine based on portions of the hiv matrix protein
WO2003002065A3 (fr) Compositions de vaccin vhc e1e2
EP1575529A4 (fr) Peptides et procedes de criblage de vaccins a base de peptides immunogenes contre la maladie d'alzheimer
WO2005007673A3 (fr) Peptides immunogenes
WO2008086386A8 (fr) Vaccins antipaludéens à base de vecteur adénoviral
GB0113798D0 (en) Antigens and vectors for vaccination
GB0118532D0 (en) Materials and methods relating to improved vaccination strategies
NO20073914L (no) Biologisk aktive peptider
ATE420191T1 (de) Promotoren zur expression im modifizierten vacciniavirus ankara
WO2006110915A3 (fr) Formulations de vaccins pour leishmania
WO2003093298A3 (fr) Peptides immunogenes
MXPA03008832A (es) Vacunas contra leishmania.
WO2005014654A3 (fr) Complexes multimeres d'antigenes et d'un adjuvant
DK1578772T3 (da) Cytokiner og cytokinreceptorer med reduceret immunogenicitet
DE50312368D1 (de) Rekombinante mva-stamme als potentielle impfstoffe gegen p. falciparum -malaria
WO2002092628A3 (fr) Antigenes de plasmodium falciparum et leurs applications vaccinales et diagnostiques
DK1697405T3 (da) LSA-5 leverstadium- og blodstadium-antigen fra Plasmodium falciparum, immunogent præparat omfattende dette antigen samt vacciner mod malaria
FR2809960B1 (fr) Composition adjuvante de la reponse immunitaire comprenant la proteine fha ou un fragment de la proteine fha sous forme libre, et composition immunogene ou vaccinale contenant une telle composition adjuvante
TH79424B (th) วัคซีน
ITRM20010454A0 (it) Tecnica di presentazione ed esecuzione delle procedure di offerta e vendita di immobili per via telematica.